Free tool
FAERS Monitor: Chemet
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019998 or its brand name (Chemet, Succimer). Reports on generic versions are filed under their own applications.
Reports
71
Serious
35
49% of reports
Hospitalization
13
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use23
- product availability issue9
- arthralgia6
- hypertension5
- no adverse event5
- weight increased5
- condition aggravated4
- dizziness4
- skin striae4
- abdominal pain upper3
- arrhythmia3
- asthenia3
- atrial fibrillation3
- back pain3
- cushingoid3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 4 |
| 2011 | 1 |
| 2012 | 3 |
| 2014 | 1 |
| 2016 | 15 |
| 2017 | 7 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 16 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,088 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| skin striaeSignal | 4 | 798.8 | 307.9 | 2,433 |
| cushingoidSignal | 3 | 277.1 | 91.5 | 572 |
| product availability issueSignal | 9 | 117.1 | 63.6 | 924 |
| arrhythmiaSignal | 3 | 18.8 | 6.2 | 34 |
| atrial fibrillationSignal | 3 | 9.1 | 3.0 | 14 |
| no adverse eventSignal | 5 | 8.2 | 3.5 | 25 |
| off label useSignal | 23 | 7.8 | 5.6 | 135 |
| hypertensionSignal | 5 | 7.0 | 3.0 | 20 |
| weight increasedSignal | 5 | 6.6 | 2.8 | 19 |
| abdominal pain upperSignal | 3 | 4.3 | 1.4 | 5 |
| arthralgiaSignal | 6 | 4.3 | 2.0 | 12 |
| condition aggravatedSignal | 4 | 3.9 | 1.5 | 6 |
| back pain | 3 | 3.8 | 1.3 | 4 |
| dizziness | 4 | 2.4 | 0.9 | 2 |
| asthenia | 3 | 2.4 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.